TB

An educational video and presentation intended to train health care providers to perform Tuberculin skin testing.

An educational video and presentation intended to train health care providers to perform Tuberculin skin testing.

An educational video intended to train health care providers to perform Tuberculin skin testing.

A fact sheet on the QuantiFERON (also called QFT test), including information on how test results are interpreted. There is also content on the difference between latent TB infection and TB disease.

This information sheet discusses the bacille Calmette-Guerin (BCG) vaccine for TB, which is used in many countries to prevent childhood tuberculous meningitis and miliary TB. It explains why the BCG is not generally recommended for use in the United States; suggests that the BCG should be considered under specific circumstances; and provides recommendations for when the BCG should be used with children and health care workers, and contraindications when it should not be used, such as for immunosuppressed persons and pregnant women.

This information sheet discusses general information about TB. It explains how TB affects the body, its symptoms, and method of transmission as well as the difference between latent TB infection (LTBI) and TB disease. The information sheet also explains what to do after being in contact with an individual who has LTBI, or active TB disease. It describes TB testing, including TB skin test or blood test; the bacille Calmette-Guerin (BCG) TB vaccine; and treatment of LTBI and active TB disease.

This information sheet discusses multidrug-resistant TB (MDR TB), a strain of TB that is resistant to at least two of the best anti-TB drugs, isoniazid and rifampicin. It describes TB disease, MDR TB, extensively drug resistant TB (XDR TB), TB transmission, how drug resistance happens, and who is at risk for getting MDR TB. The information sheet also explains how MDR TB can be prevented, TB vaccine, the symptoms of TB disease, and what an individual should do after being exposed to someone with TB.

This information sheet discusses infection control measures for health care settings to ensure prompt detection, take airborne precautions, and treat persons with suspected or diagnosed tuberculosis infection. It suggests that policies and procedures for TB control should be developed, reviewed periodically, and evaluated to minimize transmission risk.

This information sheet discusses TB and the risk for international travelers. It explains TB transmission, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the disease, and how drug resistance occurs. The information sheet considers whether international travelers are at risk of MDR or XDR TB while traveling, the risk of acquiring TB on an airplane, how TB can be prevented, TB vaccine, and what an individual should do before traveling internationally and if an individual thinks that he/she may have been exposed to someone with TB disease.

This information sheet discusses TB and the risk for international travelers. It explains TB transmission, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the disease, and how drug resistance occurs. The information sheet considers whether international travelers are at risk of MDR or XDR TB while traveling, the risk of acquiring TB on an airplane, how TB can be prevented, TB vaccine, and what an individual should do before traveling internationally and if an individual thinks that he/she may have been exposed to someone with TB disease.